Well spotted, Player. Thanks for sharing that.
At the current price of TFC shares, all of the health products under development are a free option with no value given by the market. Yet one over-the-counter (OTC) product is on the market and doing well, and the following are under development:
* Pharma products for six different indications (one post-Stage 2 and three at Stage 2);
* Further OTC products for three more indications (two ready for partner selection and market release within the next 12 months).
The estimated US market size for Acne is >$4B (TFS OTC product already launched), and is >$3.8B for Eczema (TFS product at pre-launch stage). The US market size for Psoriasis is > $5B.
I know from experience that many pharma products can take longer than expected to get to market. But TFS is already well placed for further OTC products for eczema and skin warts to be released over the next year or so. Not bad for a free option.
- Forums
- ASX - By Stock
- TFC
- Another pharmaceutical application trial
Another pharmaceutical application trial, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TFC (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online